Gilead at outperform by RBC

RBC Capital Markets analyst Jason Kantor rated Gilead Sciences, Inc. at outperform, average risk on news of the company's reported significant earnings per share upside of $0.64, compared to RBC and consensus estimates of $0.56. Kantor is encouraged by Gilead's strong top and bottom line performance in the quarter and the company's recent "product/company acquisition shopping spree." Shares of the Foster City, Calif.-based biopharmaceutical company were up 58 cents, or 0.86%, at $68.30. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.